177Lu-rhPSMA-10.1 临床前评估:一种前列腺癌放射性药物的生物分布与疗效
在荷瘤与非荷瘤小鼠模型中评估新型放射性杂合 PSMA 靶向药物 177Lu-rhPSMA-10.1 的生物分布与疗效。其肾脏摄取与滞留低于 177Lu-PSMA-I&T,肿瘤摄取更高,可剂量依赖性抑制肿瘤生长并延长中位生存,作者认为是有前景的下一代放射性药物治疗。
要点
- 177Lu-rhPSMA-10.1 在血液和正常组织中 48 小时内快速清除,肾脏为正常器官中摄取最高者。
- 肾脏摄取与滞留低于 177Lu-PSMA-I&T:BALB/c 小鼠 12 小时低 6.5 倍,22Rv1 移植瘤 15 小时低 6.4 倍(P < 0.01)。
- 22Rv1 移植瘤中肿瘤摄取为 177Lu-PSMA-I&T 的 2.3 倍(15 小时,P < 0.05)。
核心结论
- 在临床前模型中,177Lu-rhPSMA-10.1 显示出有利的肿瘤-肾脏摄取比和显著抗肿瘤作用,提示其是有前景的下一代放射性药物治疗。
研究设计与样本
- 在非荷瘤 BALB/c 小鼠及前列腺癌人源异种移植小鼠模型(LNCaP 和 22Rv1 移植瘤)中进行临床前分析。
- 在 BALB/c 小鼠和 22Rv1 移植瘤中评估 177Lu-rhPSMA-10.1 的纵向生物分布,注射 1 MBq 后 1–168 小时取材测放射性(每时间点 4 只)。
- 纵向生物分布与 177Lu-PSMA-I&T(1 MBq)在 BALB/c 小鼠及 22Rv1 移植瘤单一时间点(15 小时)比较。
- 在 LNCaP 移植瘤中评估单次给予 15、30 或 45 MBq 177Lu-rhPSMA-10.1 的疗效,在 22Rv1 移植瘤中评估 30 MBq 177Lu-rhPSMA-10.1、177Lu-PSMA-617 或 177Lu-PSMA-I&T(每组 8 只)。
- 疗效与溶媒对照比较,基于给药后至 49 天的相对肿瘤体积和生存;统计采用 t 检验、双因素重复测量方差分析(肿瘤体积,分析至每组剩 3 只)或 Kaplan-Meier 对数秩分析(生存)。
主要发现
- 177Lu-rhPSMA-10.1 在 BALB/c 小鼠和 22Rv1 移植瘤中 48 小时内从血液和其他正常组织快速清除,肾脏为正常器官中摄取最高者。
- 肾脏摄取与滞留低于 177Lu-PSMA-I&T:BALB/c 小鼠 12 小时低 6.5 倍,22Rv1 移植瘤 15 小时低 6.4 倍(P < 0.01)。
- 22Rv1 移植瘤中观察到高且持续的 177Lu-rhPSMA-10.1 肿瘤摄取,15 小时为 177Lu-PSMA-I&T 的 2.3 倍(P < 0.05)。
- LNCaP 移植瘤中 177Lu-rhPSMA-10.1 自第 11 天起显著抑制肿瘤生长(P < 0.05),呈剂量依赖性;22Rv1 移植瘤中自第 18 天起显著抑制(P < 0.05);两种模型中均较溶媒对照显著延长中位生存。
- 22Rv1 移植瘤中 177Lu-rhPSMA-10.1 较溶媒对照的肿瘤抑制程度大于 177Lu-PSMA-I&T(自第 25 天起显著抑制,P < 0.05),与 177Lu-PSMA-617 程度相似(自第 18 天起,P < 0.05);总体较 177Lu-PSMA-I&T 抑制肿瘤生长时间长于 177Lu-PSMA-617(前者自第 39 天起持续抑制,P < 0.05;后者仅第 49 天,P < 0.05)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
177Lu-rhPSMA-10.1 is a novel radiohybrid prostate-specific membrane antigen (PSMA)-targeted radiopharmaceutical therapy for prostate cancer. We conducted preclinical analyses on non-tumor-bearing BALB/c mice and on prostate cancer human xenograft mouse models (LNCAP and 22Rv1 xenografts) to evaluate its biodistribution and therapeutic efficacy. Methods: Longitudinal biodistribution of 177Lu-rhPSMA-10.1 was evaluated in BALB/c mice and 22Rv1 xenografts. Tissues of interest were harvested, and radioactivity was measured 1-168 h after injection of 1 MBq of 177Lu-rhPSMA-10.1 (4 per time point). Longitudinal biodistribution was compared with 177Lu-PSMA-I&T (1 MBq) in BALB/c mice and at a single time point (15 h) in 22Rv1 xenografts. The therapeutic efficacy of a single administration of 15, 30, or 45 MBq of 177Lu-rhPSMA-10.1 in LNCaP xenografts and 30 MBq of 177Lu-rhPSMA-10.1, 177Lu-PSMA-617, or 177Lu-PSMA-I&T in 22Rv1 xenografts (8 per group) was evaluated. Efficacy versus vehicle was evaluated on the basis of relative tumor volume and survival up to 49 d after administration. Statistical significance was evaluated with t testing (biodistribution data), 2-way repeated-measures ANOVA (tumor volume [analyzed until 3 per group remained]), or Kaplan-Meier log-rank analyses (survival). Results: Biodistribution of 177Lu-rhPSMA-10.1 in the BALB/c and 22Rv1 xenografts showed rapid clearance from blood and other normal tissues within 48 h, with the kidney showing the highest normal-organ uptake. Kidney uptake and retention were lower for 177Lu-rhPSMA-10.1 than for 177Lu-PSMA-I&T (6.5-fold lower at 12 h in BALB/c mice and 6.4-fold lower at 15 h in 22Rv1 xenografts; P < 0.01). High and sustained 177Lu-rhPSMA-10.1 tumor uptake was observed in 22Rv1 xenografts. This uptake was 2.3-fold higher than that of 177Lu-PSMA-I&T (15 h; P < 0.05). When efficacy was evaluated, 177Lu-rhPSMA-10.1 significantly suppressed tumor growth versus vehicle from day 11 (P < 0.05) in LNCaP xenografts in a dose-dependent manner and from day 18 (P < 0.05) in 22Rv1 xenografts and significantly prolonged median survival versus vehicle in both models. In 22Rv1 xenografts, 177Lu-rhPSMA-10.1 suppressed tumor growth versus vehicle to a greater extent than did 177Lu-PSMA-I&T (significant growth inhibition from day 25 [P < 0.05]) and similarly in extent to 177Lu-PSMA-617 (from day 18 [P < 0.05]). Overall, compared with 177Lu-PSMA-I&T, 177Lu-rhPSMA-10.1 suppressed tumor growth for longer than 177Lu-PSMA-617 (inhibition from day 39 onward [P < 0.05] versus on day 49 only [P < 0.05]). Conclusion: In preclinical models, 177Lu-rhPSMA-10.1 shows a favorable tumor-to-kidney uptake ratio, and significant antitumor effects, indicating it to be a promising next-generation radiopharmaceutical therapy.
引用
- Foxton C, Waldron B, Veggerby Grønlund R, et al. Preclinical Evaluation of 177Lu-rhPSMA-10.1, a Radiopharmaceutical for Prostate Cancer: Biodistribution and Therapeutic Efficacy. J Nucl Med. 2025. PMID: 40049746. doi:10.2967/jnumed.124.268508
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。